$0.670
-0.302 (-45.12%)Zum Schluss
VRPX-News
VRPX-Events
Virpax Pharmaceuticals announces 1-for-25 reverse stock split
Virpax Pharmaceuticals announced that it will effect a 1-for-25 reverse stock split of its common stock, par value $0.0001 per share that will become effective at 12:01 a.m. Eastern Time on March 20. The Company's Common Stock will continue to trade on the Nasdaq Capital Market under the symbol "VRPX" and will begin trading on a split-adjusted basis when the Nasdaq opens on March 21. The new CUSIP number for the Common Stock following the reverse split will be 928251305.
Virpax receives positive Probudur results for dose range study
Virpax Pharmaceuticals announced positive results from a beagle dog dose range finding study. Probudur is the company's long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediate and extended pain relief. The company continues to work towards its Investigational New Drug application and this was another important step towards that milestone. The DRF study was conducted to evaluate the tolerance of Probudur when administered by subcutaneous injection to beagle dogs in a dose escalating manner. All the dogs in the DRF study demonstrated positive tolerance to Probudur and no adverse effects were noted. The results of this study suggest that doses of LBL100 up to 90 mg/kg are well tolerated by beagle dogs.
Virpax Pharmaceuticals reports Molecular Envelope Technology human study data
The company states: "Virpax Pharmaceutical would like to congratulate Nanomerics on completing a human study using the Molecular Envelope Technology and showing no moderate to severe adverse events. Virpax uses MET in its Envelta and NobrXiol. Envelta is an enkephalin drug product based on a type of nanotechnology delivery approach. The MET is designed to protect and help carry the drug to the brain with the goal of promptly suppressing pain by binding to the delta opioid receptors. Envelta has demonstrated analgesic potential in animal models without the development of opioid tolerance or reward seeking behavior. It is currently being developed in a cooperative research and development agreement with the National Center for Advancing Translational Sciences, an institute/center of the National Institutes of Health U.S. Department of Health and Human Services. In addition, Virpax uses MET with NobrXiol. NobrXiol is being developed for delivery of cannabidiol in the management of epilepsy in children and adults. NobrXiol utilizes the MET as its delivery system to cross the blood brain barrier, propelling the cannabidiol nanoparticles through the nose to the brain via the olfactory nerve. The drug has received pre-Investigational New Drug application guidance from the U.S. Food and Drug Administration. Nanomerics's Phase I trial, the SUNLIGHT trial, involved 28 days of administration of OC134, powered by the MET and MET alone as eye drops to healthy volunteers. Dosing twice daily (12 h apart) of the healthy study participants with MET eye drops and OC134 eye drops commenced in December 2024 and was completed in January 2025. The SUNLIGHT trial was a phase I clinical trial; these trials are used to test for the safety, side effects, best dose, and timing of a new treatment. It may also test the best way to give a new treatment (for example, by mouth, infusion into a vein, or injection) and how the treatment affects the body."
Virpax Pharmaceuticals confirms results with U.S. Army with Probudur
Virpax Pharmaceuticals announced the completion of the full study that followed the initial Probudur pilot study performed by the U.S. Army Institute of Surgical Research, USAISR, under an existing Cooperative Research and Development Agreement, CRADA. This study was designed to determine if Probudur reduces pain behaviors in a rat model of incisional pain. The surgical procedures and assessments were identical to those in the pilot study. The study compared Probudur with free bupivacaine and EXPAREL. Various concentrations of Probudur were injected into the tissue around the incision site as well as a saline solution for the control group. The doses of Probudur showed reduction in incision-induced pain behaviors. "These positive results are consistent with what we at Virpax have previously observed and we are encouraged by these findings," commented Jatinder Dhaliwal, Chief Executive Officer of Virpax.
Virpax Pharmaceuticals announces results from Probudur minipig DRF study
Virpax Pharmaceuticals announced results from a minipig dose range finding, or DRF, study for Probudur. Probudur is the company's long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediate and extended pain relief. The DRF study was conducted to evaluate the tolerance of Probudur in an incisional wound healing model in minipigs. Probudur was injected locally into the tissue surrounding the incision area. All of the minipigs demonstrated tolerance to Probudur and no adverse effects were noted. The development program for Probudur continues to support the Company's belief that Probudur has the potential to provide both immediate and sustained pain relief at the incisional area. Probudur is being developed to achieve the overall goal of safe and effective pain control during the perioperative period and significantly reduce or eliminate the need for opioids after surgery in approved indications. Probudur is a local anesthetic that binds to the sodium channel, preventing pain signals from reaching the brain. In preclinical studies, Probudur has shown long duration pain control for at least 96 hours, with a rat incisional model demonstrating analgesia for up to five days and in vitro studies demonstrating a slow release of bupivacaine that lasted for up to six days.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.